Parkinson's disease (PD) is one of the most debilitating brain diseases. Despite the
availability of symptomatic treatments, response towards the health of PD patients remains …

Glutamatergic hyperactivity in the nucleus striatum, the main basal ganglia input, has been
involved in the progression of Parkinson's disease (PD) and the onset of L-Dopa-induced …

Parkinson's disease (PD) is a complex, multisystem disorder characterised by α-synuclein
(SNCA) pathology, degeneration of nigrostriatal dopaminergic neurons, multifactorial …

Glutamate is a biomarker for many nervous system diseases, and sensitively detecting
glutamate is meaningful in the clinic. Therefore, a unique 3D framework of Cd-MOF (1) is …

Disturbance of glutamate neurotransmission in Parkinson's disease (PD) and l-DOPA
induced dyskinesia (LID) is well documented. This review focuses on advances during the …

Parkinson's disease (PD) is a common neurodegenerative disorder of middle-aged and
elderly people, clinically characterized by resting tremor, myotonia, reduced movement, and …

Safinamide has been recently approved as an add-on to levodopa therapy for Parkinson
disease. In addition to inhibiting monoamine oxidase type B, it blocks sodium channels and …

Introduction: Parkinson's disease (PD) is one of the most challenging neurodegenerative
disorders to treat as it manifests with a large variety of troublesome, and often disabling …

Parkinson's disease (PD) is the second most common and fastest-growing
neurodegenerative disorder. In recent years, it has been recognized that neurotransmitters …

Levodopa-induced dyskinesia (LID) is a common motor complication in patients with
Parkinson's disease on chronic levodopa therapy. The management of LID is important as …